Randomized trial will reveal diabetes drug's effects on kidney health

(Wiley) Type 2 diabetes often causes damaging effects to the kidneys, sometimes resulting in the need for dialysis or kidney transplantation. The ongoing CANVAS-R trial is testing whether canagliflozin -- a member of a new class of diabetes treatments known as sodium glucose co-transporter 2 (SGLT2) inhibitors -- can slow kidney function decline and provide other benefits to diabetic patients.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news